

The Crossroad for BioTransfer provides a unique one-stop venue for biotechnology and pharmaceutical companies, entrepreneurs and the venture capital community to gain access to intellectual property emerging from universities and research institutes. It will be an outstanding forum for stakeholders to identify technologies that promise to advance their drug discovery capability and enhance their product portfolio.

The Crossroad for BioTransfer will showcase 35 licensing opportunities in the health technology portfolios from the NRC, McGill University, Gestion Univalor, L.P. and the MTTC. Attendees will be able to schedule meetings with the presenting organizations in order to discuss these opportunities and hundreds more available.

Overview of the Program Agenda

7:30 am	<i>Registration</i>
8:30 am	Welcoming Address
8:35 am	<i>Research, Innovation and Partnership</i> France Dionne Québec Government Representative Québec Government Office in Boston
8:50 am	Session 1: Diagnostic Applications and Anti-Infectives (8 technologies)
9:00 am to 5:00 pm	One-on-One Meetings
10:10 am	<i>Coffee Break and Networking</i>
10:30 am	Session 2: CNS, Ophthalmology and Gene Therapy (8 technologies)
11:50 am	<i>U.S. Venture Capital Investing in Canadian Life Science Companies - Challenges and Opportunities</i> Leonard M. Gold Partner, Chair of Canada Practice Dr. Ronda P. Moore Partner, Intellectual Property/SciTech Group Burns & Levinson LLP
12:10 pm	<i>Lunch and Networking</i>
1:10 pm	Session 3: Technology Platforms (10 technologies)
2:50 pm	<i>Coffee Break and Networking</i>
3:10 pm	Session 4: Oncology and Transplantation (9 technologies)
4:40 pm	<i>Title to be Confirmed</i> Phil McGurk Senior Director, Worldwide Business Development, Pfizer
5:00 pm	<i>Networking Cocktail</i>

Showcased Technologies

Session 1: Diagnostic Applications and Anti-Infectives

8:50	Diagnostic for Transplantation: Graft vs Host Disease and Renal Transplantation Anne-Marie Larose Univalor (VAL-652)
9:00	First in Class 5-OXO-ETE Receptor Antagonists Michèle Beaulieu McGill (09044)
9:10	Gene Signatures to Identify Cirrhosis Patients at Risk for Liver Cancer and Predict Cancer Recurrence Rahul Ballal MTTC-Broad
9:20	Cancer Prognostic Markers and the Method for Finding Them Edwin Wang NRC-BRI (12020)
9:30	A Chemistry Platform for Gene Silencing: Antisense and siRNA Masad Damha McGill (09065)
9:40	Novel H1V-11 Protease Inhibitors Celia A. Schiffer MTTC - UMassMed
9:50	Multi-Modal Imaging Agents for Molecular Diagnosis of Cancer Stacey Nunes NRC-IBS (12075)
10:00	Novel HSV2 Vaccine Technology Feng Yao MTTC-Brigham

Session 3: Technology Platforms

1:10	HEK293 Cell Line for Industrial Production of Recombinant Proteins, Viral Vectors and Vaccines Bernard Massie NRC-BRI (10894)
1:20	A New Platform for Generating Optimized Peptides Library Anne-Marie Larose Univalor (VAL-708)
1:30	Vaccine Adjuvant Platform Olivia Novac McGill (10084)
1:40	Human Soluble VH and VL Single-Domain Antibody Libraries for Human Therapeutic Applications Jamshid Tanha NRC-IBS (11686)
1:50	Platform Technology for Small Molecule Modulators of Autophagy Junying Yuan MTTC-Harvard
2:00	Cumate-Inducible Expression System in Eukaryotic Cells Benard Massie NRC-BRI (11648)
2:10	A New Vaccine Platform to Ensure Epitope Delivery for both MHC Presentation (e.g. Hepatitis C Novel Antigen) Louis Provencher Univalor (VAL-678)
2:20	Synthetic Ether Lipid (Archaeosome) Delivery/Adjuvant Technology Yves Geoffrion NRC-IBS (11784)
2:30	Efficient, Fast and Productive Method for Large-Scale Transfection of CHO and HEK293 Cells Yves Durocher NRC-BRI (11992)
2:40	Engineered Biosynthetic Pathway for Sialic Acid Analogs and its Use for the Development of Anti-Infectives Ian Schoenhofen NRC-IBS (12033)

Session 2: CNS, Ophthalmology and Gene Therapy

10:30	Lodamin: A Novel Oral Drug for Oncology, Ophthalmology and Autoimmune Diseases Ofra Benny-Ratsaby MTTC-Children's
10:40	Novel Peptide(s) for the Treatment of Alzheimer's Disease Stacey Nunes NRC-IBS (11630)
10:50	Trk Family Receptor Ligands for Treatment of Neurodegenerative Diseases Uri Saragovi McGill (10051)
11:00	New Targets for Inflammatory Disease of the Nervous System Including Multiple Sclerosis Anne-Marie Larose Univalor (VAL-737)
11:10	Bacterial Components for Allergic Airway Disorder Therapy Yves Geoffrion NRC-IBS (11894)
11:20	New Target and Compounds for Treating Age-Related Macular Degeneration Louis Provencher Univalor (VAL-620)
11:30	Muscle-Mediated Gene Therapy Rénald Gilbert NRC-BRI (11887)
11:40	Atoxic Recombinant Holotoxins of <i>Clostridium Difficile</i> as Immunogens Feng Hanping MTTC - Tufts University

Session 4: Oncology and Transplantation

3:10	Chemosensitizing Agents for Multidrug Resistance (MDR) & Chemotherapy Larry Chow McGill (09086)
3:20	TGF-β Biologic Targeted Therapy for Oncology, Cardiovascular Disease and Nephrology Indications Maureen O'Connor NRC-BRI (11817)
3:30	Use of Novel Proteasome Inhibitors to Treat Cancer and Disorders in the Immune System Clermont Beaulieu Univalor (VAL-789)
3:40	Novel Peptide(s) for the Treatment of Cancer Danica Stanimirovic NRC-IBS (11627)
3:50	A Simple, Scalable and High Yield Method for High Level Production of Human Recombinant Interferon Yves Durocher NRC-BRI (11993)
4:00	Fusion Protein Platform: Anti-Cancer, Anti-Inflammatory and Immunosuppressive Jacques Galipeau McGill (06087S)
4:10	Antimetabolites C3' Louis Provencher Univalor (VAL-740)
4:20	Novel Anti-Mitotic Peptides for the Treatment of Cancer Giovanna Sebastiani McGill (04086)
4:30	Expansion of Hematopoietic Stem Cells Carla DeMaria MTTC-Whitehead